SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Genmab Reports Nine-Month 2026 Financial Results

Genmab released its interim report for the nine months ended September 30, 2026. The report highlights approval in Europe of TEPKINLY plus R(2) for second-line follicular lymphoma.

GMAB

Story updates

04:02:31 PM UTC
SquawkNews
GENMAB: REVENUE WAS $3,238 MLN FOR FIRST NINE MONTHS OF 2026 COMPARED TO $2,662 MLN FOR FIRST NINE M

Related stories